Safety and Toxicology of Ocular Gene Therapy with Recombinant AAV Vector rAAV.hCNGA3 in Nonhuman Primates (vol 30, pg 50, 2019)

被引：0
|
作者：
Peters, Tobias
Seitz, Immanuel Philipp
Michalakis, Stylianos
Biel, Martin
Wilhelm, Barbara
Reichel, Felix
Ochakovski, Guy Alexander
Zrenner, Eberhart
Ueffing, Marius
Korbmacher, Birgit
Korte, Sven
Bartz-Schmidt, Karl Ulrich
Fischer, Manuel Dominik
机构：
来源：
HUMAN GENE THERAPY | 2020年 / 31卷 / 23-24期
关键词：
D O I：
10.1089/hum.humc.2018.188.correx
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
引用
收藏
页码：1312 / 1312
页数：1
相关论文
共 7 条
  • [1] Safety and Toxicology of Ocular Gene Therapy with Recombinant AAV Vector rAAV.hCNGA3 in Nonhuman Primates
    Tobias, Peters
    Philipp, Seitz Immanuel
    Stylianos, Michalakis
    Martin, Biel
    Barbara, Wilhelm
    Felix, Reichel
    Alexander, Ochakovski Guy
    Eberhart, Zrenner
    Marius, Ueffing
    Birgit, Korbmacher
    Sven, Korte
    Ulrich, Bartz-Schmidt Karl
    Dominik, Fischer Manuel
    Bartz-Schmidt, Karl Ulrich
    Bolz, Sylvia
    Fischer, Dominik
    Kohl, Susanne
    Kuehlewein, Laura
    Muehlfriedel, Regine
    Neubauer, Jonas
    Ochakovski, Alex
    Paquet-Durand, Francois
    Seeliger, Mathias
    Sothilingam, Vithiyanjali
    Ueffing, Marius
    Weisschuh, Nicole
    Wissinger, Bernd
    Zhour, Ahmad
    Zobor, Ditta
    Zrenner, Eberhart
    Biel, Martin
    Michalakis, Stylianos
    Schoen, Christian
    Kahle, Nadine
    Peters, Tobias
    Wilhelm, Barbara
    Tsang, Steven
    Gloeckner, Christian Johannes
    HUMAN GENE THERAPY CLINICAL DEVELOPMENT, 2019, 30 (02) : 50 - 56
  • [2] Ocular Safety and Toxicology of Subretinal Gene Therapy With rAAV.hPDE6A in Nonhuman Primates
    Seitz, Immanuel P.
    Wozar, Fabian
    Ochakovski, Guy Alex
    Reichel, Felix F.
    Korte, Sven
    Korbmacher, Birgit
    Wilhelm, Barbara
    Suesskind, Daniela
    Bartz-Schmidt, Karl-Ulrich
    Fischer, M. Dominik
    Peters, Tobias
    TRANSLATIONAL VISION SCIENCE & TECHNOLOGY, 2025, 14 (01):
  • [3] Ocular and systemic safety of a recombinant AAV8 vector for X-linked retinoschisis gene therapy: GLP studies in rabbits and Rs1-KO mice
    Marangoni, Dario
    Bush, Ronald A.
    Zeng, Yong
    Wei, Lisa L.
    Ziccardi, Lucia
    Vijayasarathy, Camasamudram
    Bartoe, Joshua T.
    Palyada, Kiran
    Santos, Maria
    Hiriyanna, Suja
    Wu, Zhijian
    Colosi, Peter
    Sieving, Paul A.
    MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT, 2016, 3
  • [4] Assessment of toxicity and biodistribution of recombinant AAV8 vector-mediated immunomodulatory gene therapy in mice with Pompe disease (vol 1, pg 14018, 2014)
    Wang, Gensheng
    Young, Sarah P.
    Bali, Deeksha
    Hutt, Julie
    Li, Songtao
    Benson, Janet
    Koeberl, Dwight D.
    MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT, 2019, 13 : 493 - 493
  • [5] Intracerebral Gene Therapy Using AAVrh.10-hARSA Recombinant Vector to Treat Patients with Early-Onset Forms of Metachromatic Leukodystrophy: Preclinical Feasibility and Safety Assessments in Nonhuman Primates
    Zerah, Michel
    Piguet, Francoise
    Colle, Marie-Anne
    Raoul, Sylvie
    Deschamps, Jack-Yves
    Deniaud, Johan
    Gautier, Benoit
    Toulgoat, Frederique
    Bieche, Ivan
    Laurendeau, Ingrid
    Sondhi, Dolan
    Souweidane, Mark M.
    Cartier-Lacave, Nathalie
    Moullier, Philippe
    Crystal, Ronald G.
    Roujeau, Thomas
    Sevin, Caroline
    Aubourg, Patrick
    HUMAN GENE THERAPY CLINICAL DEVELOPMENT, 2015, 26 (02) : 113 - 124
  • [6] Corneal fibrosis abrogation by a localized AAV-mediated inhibitor of differentiation 3 (Id3) gene therapy in rabbit eyes in vivo (vol 30, pg 3257, 2022)
    Gupta, Suneel
    Fink, Michael K.
    Kempuraj, Duraisamy
    Sinha, Nishant R.
    Martin, Lynn M.
    Keele, Landon M.
    Sinha, Prashant R.
    Giuliano, Elizabeth A.
    Hesemann, Nathan P.
    Raikwar, Sudhanshu P.
    Chaurasia, Shyam S.
    Mohan, Rajiv R.
    MOLECULAR THERAPY, 2022, 30 (10) : 3334 - 3334
  • [7] Relevance of NHP safety studies for ocular delivery of AAV-based gene therapy in humans: Example of GS010 (rAAV2/2-ND4) local tolerability, shedding and immunogenicity for the treatment of Leber Hereditary Optic Neuropathy (LHON), after intravitreal (IVT) injection in non-human primates (NHP) and in LHON patients
    Thomasson, Nitza
    Galy, Anne
    Fitoussi, Serge
    Meunier, Sandrine
    Uretsky, Scott
    Combal, Jean-Philippe
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2015, 56 (07)
1